NeuroOne Medical Technologies Corporation

Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa, and Chief Financial Officer, Ron McClurg. Before I turn the call over to Mr. Rosa, I'd like to remind you that this conference call will include forward-looking statements within the meaning of U.S. federal security laws with respect to future operations, financial results, events, trends, and performance, which are based on management's beliefs and assumptions as of today's call or other specified date. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors which may cause actual results to differ materially from those expressed or implied by such statements. See NORA 1's corporate update press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by law, we undertake no obligation to update such forward-looking statements. With that said, I'll turn the call over to Dave Rosa, CEO of NORA 1. Dave, the floor is yours.

Thanks, Operator. During our fiscal second quarter and through today, we continued to make progress towards the commercial launch of the Evo SCEG product line. We announced the commercial release of the product line and the completion of initial training with Zimmer Biomed sales personnel for a limited launch. In addition, we also fulfilled five orders to Zimmer Biomed for the initial launch. The first clinical case was successfully performed at the Mayo Clinic by Dr. Jamie Van Gompel using a stereotactic frame system. An additional procedure using the EVO-SCEG electrode in robotic neurosurgery was performed at a different medical facility. This procedure was the first to utilize NeuroOne's EVO-SCEG electrode with Zimmer Biomed's ROSA OneBrain a robotic platform that assists surgeons in planning and performing complex, yet minimally invasive neurosurgical procedures. Finally, we presented the complete EVO product line at the American Association of Neurological Surgeons annual meeting in the Zimmer Biomed booth. To date, we are excited with the physician feedback and will provide future updates on our progress. Regarding our 1RF ablation system, we mentioned last quarter that we were planning to complete internal device verification and validation protocols for the final 1RF system. I am pleased to announce that we were able to complete these tasks as well as completing usability testing with 15 neurosurgeon thought leaders. We are waiting for additional testing to be completed along with other documentation from a few key suppliers but remain on track for an FDA 510K submission in the second calendar quarter of 2023. During the quarter, we also continued discussions with a few strategic organizations regarding their interest in our technology. Next quarter, in addition to submitting a 510K for the 1RF system, we expect to transfer the project to production activities. We also have plans to complete an in vivo animal study with key neurosurgeons. Finally, we are scheduled to present results of a preclinical study at the Neurological Disorders Summit in June. Next, I want to update you regarding our progress in the development of an electrode to provide chronic stimulation and recording to treat chronic back pain due to multiple failed back surgeries. We successfully implanted a paddle electrode in an animal model via surgical means. Benchtop testing was also successfully completed on delivering a paddle lead percutaneously through a needle. Next quarter, we expect to complete percutaneous placement in a spinal cord model by one of our physician advisors, as well as complete an animal study designed to assess the electrode's biocompatibility. In the second fiscal quarter, we discussed the potential for our electrode technology to offer the ability to deliver gene therapy or drugs as well as record the drug's impact to the patient. I am pleased to report that we successfully completed feasibility benchtop testing of our initial prototype and are planning on conducting additional testing in the small animal model. Physician enthusiasm remains high regarding the systems. During the second fiscal quarter, the company also strengthened our management team with the hire of Anthony Millar as Vice President of Operations. Anthony has held similar senior-level roles with large, well-respected medical device organizations, such as Boston Scientific, Medtronic, Minitronics, and Great Batch, where he was involved with electrode technology that was in development. We also expanded our patent portfolio with a new U.S. patent titled Improved Neural Depth Probes and Related Systems and Methods regarding our thin-film SCEG electrode technology. Finally, we also delivered an oral presentation at the annual North American Neuromodulation Society meeting, also known as NANS, titled Electrochemical Characterization of the first FDA-cleared thin-film electrodes for recording and stimulation of brain activity. Thank you for your time and attention. I would now like to turn the call over to Ron McClurg for a more in-depth review of our fiscal second quarter financial results. Ron? Thank you, Dave.

Product revenue was $466,000 in the fiscal second quarter of 2023. compared to product revenue of just $37,000 in last year's second quarter. In the first six months of fiscal 23, product revenue was $581,000 compared to $70,000 for the same period in fiscal 2022. Collaboration revenue was $1.46 million in the first six months of fiscal 2023 compared to collaboration revenue of $6,000 in the first six months of fiscal 22. Collaboration revenue is derived from the Zimmer Development Agreement and represents the portion of the exclusivity and milestone fee payments that were eligible for revenue recognition during the respective periods. Our total operating expenses in fiscal second quarter of 2023 were 3.5 million compared with 3.0 million in the same period of the prior fiscal year. R&D expenses in the fiscal second quarter of 2023 were 1.7 million compared with 1.2 million in the same period of fiscal 22. SG&A expense or selling general and administrative expense in the fiscal second quarter of 2023 was 1.8 million compared to the same 1.8 million in the prior year period. For the first six months of fiscal 23, total operating expenses were 6.8 million compared with 5.8 million in the same period of the prior year. This increase can be attributed to the R&D expense, which was 3.3 million for the first six months of fiscal 2023 compared to 2.3 million in the same period of fiscal 2022. SG&A experiences in the first six months of fiscal 2023 were 3.5 million compared to 3.6 million in the prior year period. Our net loss was 3.5 million for the fiscal second quarter of 23. compared to a net loss of 3.1 million in the prior year period. Net loss for the first six months of 2023 was 5.3 million compared with 5.9 million in the same period of fiscal 2022. As of March 31st of 2023, the company had cash, cash equivalents and short-term investments of 4.6 million compared to 11.1 million as of September 30th, 2022. The company had working capital of $4.8 million as of March 31, 2023, compared to working capital of $9.1 million as of September 30, 2022. The company had no debt outstanding as of March 31, 2023. With that, I will turn it back to Dave.